

2020 Results and 2021 Guidance

Merit Medical Investor Call

February 24, 2021

Fred Lampropoulos

Chairman and CEO

Raul Parra

CFO



CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This presentation and any accompanying management commentary include “forward-looking statements,” as defined within applicable securities laws and regulations. All statements in this presentation, other than statements of historical fact, are “forward-looking statements”, including without limitation estimates and statements regarding Merit's forecasted plans, net sales, net income or loss (GAAP and non-GAAP), gross and operating margins (GAAP and non-GAAP), earnings per share (GAAP and non-GAAP), free cash flow, compound annual growth rate, effective tax rate and other financial results, the potential impact, scope and duration of, and Merit's response to, the COVID-19 pandemic, consolidation of Merit's facilities or other expense reduction initiatives, future growth and profit expectations or forecasted economic conditions, the implementation of, and results which may be achieved through, Merit's Foundations for Growth program, or the development and commercialization of new products. In some cases, forward-looking statements can be identified by the use of terminology such as “may,” “will,” “likely,” “expects,” “plans,” “anticipates,” “intends,” “believes,” “estimates,” “projects,” “forecast,” “potential,” “plan,” or other comparable terminology. Merit's future financial and operating results and condition, as well as any forward-looking statements, are subject to inherent risks and uncertainties such as those described in its Annual Report on Form 10-K for the year ended December 31, 2019 (as amended by Amendment No. 1 to Annual Report on Form 10-K/A, the “2019 Annual Report”), its subsequent Quarterly Reports on Form 10-Q, and other filings with the U.S. Securities and Exchange Commission. Such risks and uncertainties include inherent risks and uncertainties relating to Merit's internal models or the projections in this presentation; risks and uncertainties associated with the COVID-19 pandemic and Merit's response thereto; risks relating to Merit's potential inability to successfully manage growth through acquisitions generally, including the inability to effectively integrate acquired operations or products or commercialize technology developed internally or acquired through completed, proposed or future transactions; negative changes in economic and industry conditions in the United States or other countries; expenditures relating to research, development, testing and regulatory approval or clearance of Merit's products and risks that such products may not be developed successfully or approved for commercial use; governmental scrutiny and regulation of the medical device industry, including governmental inquiries, investigations and proceedings involving Merit; litigation and other judicial proceedings affecting Merit; restrictions on Merit's liquidity or business operations resulting from its debt agreements; infringement of Merit's technology or the assertion that Merit's technology infringes the rights of other parties; actions of activist shareholders; product recalls and product liability claims; changes in customer purchasing patterns or the mix of products Merit sells; risks and uncertainties associated with Merit's information technology systems, including the potential for breaches of security and evolving regulations regarding privacy and data protection; increases in the prices of commodity components; the potential of fines, penalties or other adverse consequences if Merit's employees or agents violate the U.S. Foreign Corrupt Practices Act or other laws or regulations; laws and regulations targeting fraud and abuse in the healthcare industry; potential for significant adverse changes in governing regulations, including reforms to the procedures for approval or clearance of Merit's products by the U.S. Food & Drug Administration or comparable regulatory authorities in other jurisdictions; changes in tax laws and regulations in the United States or other countries; termination or interruption of relationships with Merit's suppliers, or failure of such suppliers to perform; fluctuations in exchange rates; concentration of a substantial portion of Merit's revenues among a few products and procedures; development of new products and technology that could render Merit's existing or future products obsolete; market acceptance of new products; volatility in the market price of Merit's common stock; modification or limitation of governmental or private insurance reimbursement policies; changes in healthcare policies or markets related to healthcare reform initiatives; failure to comply with applicable environmental laws; changes in key personnel; work stoppage or transportation risks; introduction of products in a timely fashion; price and product competition; availability of labor and materials; fluctuations in and obsolescence of inventory; and other factors referenced in the 2019 Annual Report and other materials filed with the Securities and Exchange Commission.

All forward-looking statements in this presentation or subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results will likely differ, and may differ materially, from those projected or assumed in the forward-looking statements. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. All forward-looking statements, including financial estimates, included in this presentation are made as of the date of this presentation, and are based on information available to Merit as of such date, and Merit assumes no obligation to update or disclose revisions to any forward-looking statement, except as required by law or regulation.



NON-GAAP FINANCIAL MEASURES

Although Merit’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), Merit’s management believes that certain non-GAAP financial measures provide investors with useful information regarding the underlying business trends and performance of Merit’s ongoing operations and can be useful for period-over-period comparisons of such operations. Certain financial measures included in this presentation, or which may be referenced in management’s discussion of Merit’s historical and future operations and financial results, have not been calculated in accordance with GAAP, and, therefore, are referenced as non-GAAP financial measures. Readers should consider non-GAAP measures used in this presentation in addition to, not as a substitute for, financial reporting measures prepared in accordance with GAAP. These non-GAAP financial measures generally exclude some, but not all, items that may affect Merit’s net income. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are excluded. Additionally, non-GAAP financial measures used in this presentation may not be comparable with similarly titled measures of other companies. Merit urges investors and potential investors to review the reconciliations of its non-GAAP financial measures to the comparable GAAP financial measures, and not to rely on any single financial measure to evaluate Merit’s business or results of operations. Please refer to “Notes to Non-GAAP Financial Measures” at the end of these materials for more information.

TRADEMARKS

Unless noted otherwise, trademarks used in this presentation are the property of Merit Medical Systems, Inc., in the United States and other jurisdictions.



Financial Summary

GAAP

	Q4 2020	Q4 2019	FY2020	FY2019
Revenues	\$258.0M	\$257.9M	\$963.9M	\$994.9M
Gross Margin	43.1%	43.3%	41.6%	43.5%
Operating Margin	6.2%	(1.3%)	(0.2%)	1.6%
Net Income (Loss)	\$15.4M	(\$4.2M)	(\$9.8M)	\$5.5M
Earnings (Loss) per Share	\$0.27	(\$0.08)	(\$0.18)	\$0.10

Financial Summary

NON-GAAP*

	Q4 2020	Q4 2019	FY2020	FY2019
Revenues (core constant currency) †	\$255.0M	\$257.6M	\$964.0M	\$994.4M
Gross Margin*	47.9%	48.3%	47.1%	48.6%
Operating Margin*	15.7%	12.7%	13.7%	11.8%
Net Income*	\$30.8M	\$22.1M	\$93.3M	\$82.1M
Earnings per Share*	\$0.54	\$0.40	\$1.65	\$1.46

* A non-GAAP financial measure. See "Notes to Non-GAAP Financial Measures" below for additional information regarding non-GAAP measures used in this presentation.

† A non-GAAP financial measure, representing net organic sales on a constant currency basis.



Revenue Breakdown – QTD

Region	Q4 2020	Q4 2019	\$ Change	% Change	CC % Change*
U.S.	\$147,756	\$148,981	\$(1,225)	(0.8)%	(0.1)%
APAC	53,679	51,825	1,854	3.6%	(1.2)%
EMEA	48,455	49,005	(550)	(1.1)%	(5.5)%
Rest of World	8,114	8,111	3	0.0%	7.6%
Total International	110,248	108,941	1,307	1.2%	(2.5)%
Total	\$258,004	\$257,922	\$82	0.0%	(1.1)%

* A non-GAAP financial measure. See "Notes to Non-GAAP Financial Measures" below for additional information regarding non-GAAP measures used in this presentation.



Revenue Breakdown – FY

Region	FY 2020	FY 2019	\$ Change	% Change	CC % Change*
U.S.	\$550,061	\$575,711	\$(25,650)	(4.5)%	(4.3)%
APAC	201,520	201,290	230	0.1%	(0.2)%
EMEA	184,623	187,553	(2,930)	(1.6)%	(2.2)%
Rest of World	27,671	30,298	(2,627)	(8.7)%	(0.8)%
Total International	413,814	419,141	(5,327)	(1.3)%	(1.1)%
Total	\$963,875	\$994,852	\$(30,977)	(3.1)%	(3.0)%

* A non-GAAP financial measure. See "Notes to Non-GAAP Financial Measures" below for additional information regarding non-GAAP measures used in this presentation.



2021 Financial Guidance

Financial Measure	2021 Guidance
Net Sales	\$990 million to \$1.01 billion
Net Income (GAAP)	\$47.3 million to \$55.9 million
Earnings Per Share (GAAP)	\$0.83 to \$0.98
Net Income (Non-GAAP)	\$104.8 million to \$112.7 million
Earnings Per Share (Non-GAAP)	\$1.84 to \$1.98

Merit's financial guidance for the year ending December 31, 2021 is subject to risks and uncertainties identified in this presentation and in Merit's filings with the U.S. Securities and Exchange Commission ("SEC").



2021 Revenue Guidance: Reconciliation from '21 GAAP Growth Range to '21 Core Growth Range

The following should be considered when evaluating the GAAP revenue growth range implied by our 2021 guidance:

	Low End	High End
Revenue Growth - GAAP	2.7%	4.8%
<i>Impact of FX</i>	0.5%	0.4%
Revenue Growth - Constant Currency*	2.3%	4.4%
<i>Impact of Divestitures (a)</i>	-1.1%	-1.1%
Revenue Growth - Core Constant Currency*	3.4%	5.6%
<i>Impact of Cultura (b)</i>	-1.8%	-1.8%
Revenue Growth - Core Constant Currency*, ex. Cultura	5.2%	7.4%
<i>Impact of China Tenders (c)</i>	-1.2%	-1.2%
Revenue Growth - Core Constant Currency*, ex. Cultura and China Tenders	6.5%	8.5%

Note: Sums include rounded amounts

* A non-GAAP financial measure. See "Notes to Non-GAAP Financial Measures" below for additional information regarding non-GAAP measures used in this presentation.

(a) Divestitures include sales related to ITL Healthcare Pty Ltd, NinePoint Medical Inc., and Merit's Hypotube business.

(b) Represents the forecasted impact of lower sales of Cultura Nasopharyngeal swabs in 2021, which we developed in response to the COVID-19 pandemic.

(c) Represents the forecasted impact of lower pricing due to tenders in China.

Merit's financial guidance for the year ending December 31, 2021 is subject to risks and uncertainties identified in this presentation and in Merit's filings with the SEC.



Appendix

Notes to non-GAAP financial measures

For additional details, please see the accompanying press release and forward-looking statement disclosure.

These presentation materials and associated commentary from Merit's management, as well as the press release issued today, use non-GAAP financial measures, including:

- constant currency revenue
- core revenue,
- core revenue on a constant currency basis,
- non-GAAP gross margin,
- non-GAAP operating margin,
- non-GAAP net income,
- non-GAAP earnings per share, and
- free cash flow.

Merit's management team uses these non-GAAP financial measures to evaluate Merit's profitability and efficiency, to compare operating results to prior periods, to evaluate changes in the operating results of its operating segments, and to measure and allocate financial resources internally. However, Merit's management does not consider such non-GAAP measures in isolation or as an alternative to measures determined in accordance with GAAP. Readers should consider non-GAAP measures used in this presentation in addition to, not as a substitute for, financial reporting measures prepared in accordance with GAAP. These non-GAAP financial measures generally exclude some, but not all, items that may affect Merit's net income. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management about which items are excluded. Merit believes it is useful to exclude such items in the calculation of non-GAAP earnings per share, non-GAAP gross margin, non-GAAP operating margin, and non-GAAP net income (in each case, as further illustrated in the reconciliation tables below) because such amounts in any specific period may not directly correlate to the underlying performance of Merit's business operations and can vary significantly between periods as a result of factors such as acquisition or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, severance expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, corporate transformation expenses, governmental proceedings or changes in tax or industry regulations, gains or losses on disposal of certain assets, and debt issuance costs. Merit may incur similar types of expenses in the future, and the non-GAAP financial information included in this presentation should not be viewed as a statement or indication that these types of expenses will not recur. Additionally, the non-GAAP financial measures used in this presentation may not be comparable with similarly titled measures of other companies. Merit urges investors and potential investors to review the reconciliations of its non-GAAP financial measures to the comparable GAAP financial measures, and not to rely on any single financial measure to evaluate Merit's business or results of operations.

Notes to non-GAAP financial measures (cont.)

Constant Currency Revenue

Merit's revenue on a constant currency basis is prepared by converting the current-period reported revenue of subsidiaries whose functional currency is a currency other than the U.S. dollar at the applicable foreign exchange rates in effect during the comparable prior-year period, and adjusting for the effects of hedging transactions on reported revenue, which are recorded in the U.S. The constant currency revenue adjustments of (\$3.0) million and \$1.3 million to reported revenue and to core revenue for the three and twelve-month periods ended December 31, 2020, respectively, were calculated using the applicable average foreign exchange rates for the three and twelve-month periods ended December 31, 2019, respectively.

Core Revenue and Core Revenue on a Constant Currency Basis

Merit's core revenue is defined, with respect to prior fiscal year periods, as GAAP revenue less revenue from certain dispositions. For the three and twelve-month periods ended December 31, 2019, Merit's core revenue excludes revenues attributable to the disposition of the assets related to the manufacturing of Merit's Hypotube product in August 2020 (excluded September 2019 to December 2019). With respect to current fiscal year periods, core revenue is defined as GAAP revenue, less revenue from certain acquisitions. For the three and twelve-month periods ended December 31, 2020, Merit's core revenue excludes revenues attributable to the acquisition of (1) Brightwater Medical, Inc. in June 2019 (excluded through May 2020 only), (2) Fibro vein Holdings Limited in August 2019 (excluded through July 2020 only) and (3) KA Medical, LLC in November 2020. Core revenue on a constant currency basis is defined as core revenue (as described above) adjusted to eliminate the foreign exchange impact related to that core revenue for the relevant period, using the applicable average foreign exchange rates in effect for the comparable prior-year periods presented, and includes adjustments for the effects of hedging transactions on reported revenue, which are recorded in the U.S.

Non-GAAP Gross Margin

Non-GAAP gross margin is calculated by reducing GAAP cost of sales by amounts recorded for amortization of intangible assets, certain inventory write-offs and inventory mark-up related to acquisitions.

Non-GAAP Operating Margin

Non-GAAP operating margin is calculated by adjusting GAAP operating income (loss) for certain items which are deemed by Merit's management to be outside of core operations and vary in amount and frequency among periods, such as expenses related to new acquisitions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain severance expenses, performance-based stock compensation expenses, corporate transformation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings or changes in industry regulations, as well as other items set forth in the tables below.

Non-GAAP Net Income

Non-GAAP net income is calculated by adjusting GAAP net income (loss) for the items set forth in the definition of non-GAAP operating margin above, as well as for expenses related to debt issuance costs, gains or losses on disposal of certain assets, changes in tax regulations, as well as other items set forth in the tables below.

Non-GAAP EPS

Non-GAAP EPS is defined as non-GAAP net income divided by the diluted shares outstanding for the corresponding period.

Free Cash Flow

Free cash flow is defined as cash flow from operations calculated in accordance with GAAP less capital expenditures calculated in accordance with GAAP, as set forth in the consolidated statement of cash flows.

Other Non-GAAP Financial Measure Reconciliation

The following tables set forth supplemental financial data and corresponding reconciliations of non-GAAP net income and non-GAAP earnings per share to Merit's net income and earnings per share prepared in accordance with GAAP, in each case, for the three and twelve-month periods ended December 31, 2020 and 2019. The non-GAAP income adjustments referenced in the following tables do not reflect non-performance-based stock compensation expense of approximately \$3.0 million and \$2.5 million for the three-month periods ended December 31, 2020 and 2019, respectively, and approximately \$10.6 million and \$9.4 million for the twelve-month periods ended December 31, 2020 and 2019, respectively.



Reconciliation of GAAP Net Income (Loss) to Non-GAAP Net Income

(Unaudited, in thousands except per share amounts)

	Three Months Ended December 31, 2020				Three Months Ended December 31, 2019			
	Pre-Tax	Tax Impact	After-Tax	Per Share Impact	Pre-Tax	Tax Impact	After-Tax	Per Share Impact
GAAP net income (loss)	\$ 13,245	\$ 2,133	\$ 15,378	\$ 0.27	\$ (7,962)	\$ 3,757	\$ (4,205)	\$ (0.08)
<i>Non-GAAP adjustments:</i>								
Cost of Sales								
Amortization of intangibles	12,543	(3,233)	9,310	0.16	12,825	(3,285)	9,540	0.17
Inventory write-off (a)	(24)	7	(17)	(0.00)	—	—	—	—
Inventory mark-up related to acquisitions	4	(1)	3	0.00	183	(47)	136	0.00
Operating Expenses								
Contingent consideration benefit	(8,844)	(93)	(8,937)	(0.16)	(3,805)	(702)	(4,507)	(0.08)
Impairment charges	8,199	(2,751)	5,448	0.10	20,500	(5,277)	15,223	0.27
Amortization of intangibles	1,893	(508)	1,385	0.02	2,675	229	2,904	0.06
Performance-based share-based compensation (b)	1,112	(141)	971	0.02	—	—	—	—
Corporate transformation and restructuring (c)	7,890	(1,985)	5,905	0.10	1,420	(369)	1,051	0.02
Acquisition-related	393	(101)	292	0.01	600	(154)	446	0.01
Medical Device Regulation expenses (d)	365	(98)	267	0.00	366	(47)	319	0.01
Other (e)	962	(304)	658	0.01	1,476	(380)	1,096	0.02
Other (Income) Expense								
Amortization of long-term debt issuance costs	151	(39)	112	0.00	151	(39)	112	0.00
Gain on disposal of business unit	(10)	2	(8)	(0.00)	—	—	—	—
Non-GAAP net income	<u>\$ 37,879</u>	<u>\$ (7,112)</u>	<u>\$ 30,767</u>	<u>\$ 0.54</u>	<u>\$ 28,429</u>	<u>\$ (6,314)</u>	<u>\$ 22,115</u>	<u>\$ 0.40</u>
Diluted shares (f)				56,736				55,761

Note: Certain per share impacts may not sum to totals due to rounding.



Reconciliation of GAAP Net Income (Loss) to Non-GAAP Net Income

(Unaudited, in thousands except per share amounts)

	Year Ended December 31, 2020				Year Ended December 31, 2019			
	Pre-Tax	Tax Impact	After-Tax	Per Share Impact	Pre-Tax	Tax Impact	After-Tax	Per Share Impact
GAAP net income (loss)	\$ (13,231)	\$ 3,388	\$ (9,843)	\$ (0.18)	\$ 2,193	\$ 3,258	\$ 5,451	\$ 0.10
<i>Non-GAAP adjustments:</i>								
Cost of Sales								
Amortization of intangibles	50,696	(13,065)	37,631	0.67	49,707	(12,730)	36,977	0.66
Inventory write-off (a)	1,752	(465)	1,287	0.02	—	—	—	—
Inventory mark-up related to acquisitions	191	(49)	142	0.00	1,122	(289)	833	0.01
Operating Expenses								
Contingent consideration benefit	(7,960)	466	(7,494)	(0.13)	(232)	(47)	(279)	(0.00)
Impairment charges	36,504	(7,115)	29,389	0.52	23,750	(6,113)	17,637	0.31
Amortization of intangibles	7,943	(2,141)	5,802	0.10	10,964	(2,884)	8,080	0.14
Performance-based share-based compensation (b)	3,735	(475)	3,260	0.06	—	—	—	—
Corporate transformation and restructuring (c)	14,105	(3,683)	10,422	0.18	5,551	(1,433)	4,118	0.07
Acquisition-related	1,299	(334)	965	0.02	3,497	(743)	2,754	0.05
Medical Device Regulation expenses (d)	1,379	(359)	1,020	0.02	562	(98)	464	0.01
Other (e)	24,438	(3,815)	20,623	0.37	7,282	(1,874)	5,408	0.10
Other (Income) Expense								
Amortization of long-term debt issuance costs	604	(155)	449	0.01	821	(211)	610	0.01
Gain on disposal of business unit	(517)	133	(384)	(0.01)	—	—	—	—
Tax expense related to restructuring (g)	—	—	—	—	—	93	93	0.00
Non-GAAP net income	\$ 120,938	\$ (27,669)	\$ 93,269	\$ 1.65	\$ 105,217	\$ (23,071)	\$ 82,146	\$ 1.46
Diluted shares (f)				56,374				56,235

Note: Certain per share impacts may not sum to totals due to rounding.



Reconciliation of GAAP Operating Income (Loss) to Non-GAAP Operating Income

(Unaudited, in thousands except percentages)

	Three Months Ended		Three Months Ended		Year Ended		Year Ended	
	December 31, 2020		December 31, 2019		December 31, 2020		December 31, 2019	
	Amounts	% Sales	Amounts	% Sales	Amounts	% Sales	Amounts	% Sales
Net Sales as Reported	\$ 258,004		\$ 257,922		\$ 963,875		\$ 994,852	
GAAP Operating Income (Loss)	16,007	6.2 %	(3,409)	(1.3) %	(1,562)	(0.2) %	15,434	1.6 %
Cost of Sales								
Amortization of intangibles	12,543	4.9 %	12,825	5.0 %	50,696	5.3 %	49,707	5.0 %
Inventory write-off (a)	(24)	(0.0) %	—	—	1,752	0.2 %	—	—
Inventory mark-up related to acquisitions	4	0.0 %	183	0.1 %	191	0.0 %	1,122	0.1 %
Operating Expenses								
Contingent consideration benefit	(8,844)	(3.4) %	(3,805)	(1.5) %	(7,960)	(0.8) %	(232)	(0.0) %
Impairment charges	8,199	3.2 %	20,500	7.9 %	36,504	3.8 %	23,750	2.4 %
Amortization of intangibles	1,893	0.7 %	2,675	1.0 %	7,943	0.8 %	10,964	1.1 %
Performance-based share-based compensation (b)	1,112	0.4 %	—	—	3,735	0.4 %	—	—
Corporate transformation and restructuring (c)	7,890	3.1 %	1,420	0.6 %	14,105	1.5 %	5,551	0.6 %
Acquisition-related	393	0.2 %	600	0.2 %	1,299	0.1 %	3,497	0.4 %
Medical Device Regulation expenses (d)	365	0.1 %	366	0.1 %	1,379	0.1 %	562	0.1 %
Other (e)	962	0.4 %	1,476	0.6 %	24,438	2.5 %	7,282	0.7 %
Non-GAAP Operating Income	<u>\$ 40,500</u>	<u>15.7 %</u>	<u>\$ 32,831</u>	<u>12.7 %</u>	<u>\$ 132,520</u>	<u>13.7 %</u>	<u>\$ 117,637</u>	<u>11.8 %</u>

Note: Certain percentages may not sum to totals due to rounding.

Footnotes to Reconciliations of GAAP Net Income (Loss) to Non-GAAP Net Income and GAAP Operating Income (Loss) to Non-GAAP Operating Income

- a) Represents write-off of inventory related to the closure of the ITL Healthcare Pty Ltd. (“ITL”) procedure pack operations in Australia and suspension of Merit’s distribution agreement with NinePoint Medical, Inc.
- b) Represents performance-based share-based compensation expense, including stock-settled and cash-settled awards.
- c) Includes severance related to corporate initiatives, write-offs and valuation adjustments of other long-term assets associated with restructuring activities, expenses related to Merit’s Foundations for Growth program and other transformation costs.
- d) Represents incremental expenses incurred to comply with the Medical Device Regulation (MDR) in Europe.
- e) Represents expense from acquired in-process research and development, charges related to abandoned patents, costs incurred in responding to an inquiry from the U.S. Department of Justice (“DOJ”), and, in 2020 only, fees associated with settlement of a shareholder dispute and \$18.7 million of settlement costs related to the DOJ inquiry.
- f) For the twelve-month period ended December 31, 2020 and the three-month period ended December 31, 2019, the non-GAAP net income per diluted share calculation includes approximately 940,000 and 551,000 shares, respectively, that were excluded from the GAAP net income (loss) per diluted share calculation.
- g) Net tax expense related to non-recurring tax withholdings in connection with restructuring of certain international subsidiaries.

Reconciliation of Reported Revenue to Core Revenue (Non-GAAP), Constant Currency Revenue (Non-GAAP), and Core Revenue on a Constant Currency Basis (Non-GAAP) (Unaudited, in thousands except percentages)

	% Change	Three Months Ended December 31,		% Change	Year Ended December 31,	
		2020	2019		2020	2019
Reported Revenue	0.0 %	\$ 258,004	\$ 257,922	(3.1) %	\$ 963,875	\$ 994,852
<i>Add: Impact of foreign exchange (a)</i>		(2,981)	—		1,308	—
Constant Currency Revenue	(1.1) %	<u>\$ 255,023</u>	<u>\$ 257,922</u>	(3.0) %	<u>\$ 965,183</u>	<u>\$ 994,852</u>

	% Change	Three Months Ended December 31,		% Change	Year Ended December 31,	
		2020	2019		2020	2019
Reported Revenue	0.0 %	\$ 258,004	\$ 257,922	(3.1) %	\$ 963,875	\$ 994,852
<i>Less: Revenue from certain acquisitions and dispositions (b)</i>		(12)	(298)		(1,229)	(433)
Core Revenue	0.1 %	<u>\$ 257,992</u>	<u>\$ 257,624</u>	(3.2) %	<u>\$ 962,646</u>	<u>\$ 994,419</u>
<i>Add: Impact of foreign exchange (a)</i>		(2,981)	—		1,308	—
Core Revenue on a Constant Currency Basis	(1.0) %	<u>\$ 255,011</u>	<u>\$ 257,624</u>	(3.1) %	<u>\$ 963,954</u>	<u>\$ 994,419</u>

(a) The constant currency revenue adjustments of (\$3.0) million and \$1.3 million to reported revenue and to core revenue for the three and twelve-month periods ended December 31, 2020, respectively, were calculated using the applicable average foreign exchange rates for the three and twelve-month periods ended December 31, 2019, respectively, and include adjustments for the effects of hedging transactions on reported revenue, which are recorded in the U.S.

(b) Merit's core revenue is defined with respect to prior fiscal year periods, as GAAP revenue, less revenue from certain dispositions. For the three and twelve-month periods ended December 31, 2019, Merit's core revenue excludes revenues attributable to the disposition of assets related to the manufacturing of Merit's Hypotube products in August 2020 (excluded September 2019 to December 2019). With respect to current fiscal year periods, core revenue is defined as GAAP revenue, less revenue from certain acquisitions. For the three and twelve-month periods ended December 31, 2020, Merit's core revenue excludes revenues attributable to the acquisition of (1) Brightwater Medical, Inc. in June 2019 (excluded through May 2020 only), (2) Fibrovein Holdings Limited in August 2019 (excluded through July 2020 only) and (3) KA Medical, LLC in November 2020. Core revenue on a constant currency basis is defined as core revenue (as described above) adjusted to eliminate the foreign exchange impact related to that core revenue for the relevant period, using the applicable average foreign exchange rates in effect for the comparable prior-year periods presented, and includes adjustments for the effects of hedging transactions on reported revenue, which are recorded in the U.S.

Reconciliation of GAAP Gross Margin to Non-GAAP Gross Margin

(Unaudited, as a percentage of reported revenue)

	Three Months Ended		Year Ended	
	December 31,		December 31,	
	2020	2019	2020	2019
Reported Gross Margin	43.1 %	43.3 %	41.6 %	43.5 %
<i>Add back impact of:</i>				
Amortization of intangibles	4.9 %	5.0 %	5.3 %	5.0 %
Inventory write-off (a)	(0.0) %	—	0.2 %	—
Inventory mark-up related to acquisitions	0.0 %	0.0 %	0.0 %	0.1 %
Non-GAAP Gross Margin	47.9 %	48.3 %	47.1 %	48.6 %

Note: Certain per share impacts may not sum to totals due to rounding.

(a) Represents write-off of inventory related to the closure of the ITL procedure pack operations in Australia and suspension of Merit's distribution agreement with NinePoint Medical, Inc.



MERTAMEDICA[®]